BioArctic: Interim Report for the period April - June 2026

EarningsLeqembiPositive

AI Analysis

Summary

BioArctic released an interim report for Q2 2026 noting new approvals for Leqembi and additional strategic partnerships, with Eisai providing a sales forecast of JPY 143.5 billion for fiscal year 2026.

Financial Highlights

Guidance

Eisai forecast Leqembi sales of JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)

Outcome Details

Interim report for Q2 2026 with sales forecast from Eisai

Importance:3/10

Sentiment:

0.30

interim reportsales forecastLeqembistrategic partnershipsEisai partnership

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Clinical Trials on August 26, 2026 6:46 AM

Read Original